Researchers ID Potential Target for Therapy in Patients with Deadly Type of Prostate Cancer (study team headed by Robert Reiter, MD, MBA). This story was covered by UCLA Newsroom and DuckNet.
WebMD reported May 7 on research by Dr. Robert Reiter, professor-in-residence of urology and co-director of the prostate and genitourinary oncology program at UCLA's Jonsson Comprehensive Cancer Center, showing that preoperative MRIs of the prostate may improve surgeons' ability to determine if they can operate and spare the nerves that control men's erections. Reiter was quoted.
The UCLA Cancer Discoveries magazine profiles the research of investigators including those who work closely with the SPORE.
Dr. David Heber discusses how low fat diets with exercise help prevent prostate cancer in this educational video from TheDoctorsChannel.com.
A study by Dr. William Aronson on whether a low-fat diet and fish oil supplements can help men with prostate cancer was featured in the Dec. 15 issue of the National Cancer Institute Cancer Bulletin. Aronson is a professor of urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center.
UCLA Newsroom reported that Astellas, Medivation to develop, commercialize MDV3100 for treatment of prostate cancer. The companies will use a compound developed at UCLA laboratories by SPORE investigators.
A study by Dr. Allan Pantuck, associate professor of urology and a researcher at UCLA's Jonsson Cancer Center researcher, showing that pomegranate juice slows prostate cancer progression was featured May 28 in Renal and Urology News.
HealthDay News reported April 29 on a study by Dr. Allan Pantuck, associate professor of urology and a researcher at UCLA's Jonsson Cancer Center, that found daily doses of pomegranate juice helped limit increases in PSA levels among men treated for prostate cancer.
Dr. Robert Reiter, a professor of urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center, commented April 28 on results of a prostate cancer vaccine study in a story on TheStreet.com.
Dr. Matthew Rettig, an associate professor of urology and a researcher at UCLA's Jonsson Comprehensive Cancer Center, commented April 28 in the Seattle Times on the results of a prostate cancer vaccine study.
A new drug with a radically different way of attacking prostate cancer has done well in an initial trial and is ready for larger-scale testing, researchers report.
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs. Chemists and biologists at UCLA and colleagues at several other institutions, including Memorial Sloan-Kettering Cancer Center, have created a new drug to treat a particularly lethal form of the disease, known as castration-resistant prostate cancer, or CRPC. Also referred to as hormone-refractory prostate cancer, CRPC is resistant to further treatment by anti-hormone drugs such as Casodex and Eulexin. This story was reported by UCLA Newsroom and ScienceMag.org.
Levels of Circulating Tumor Cells Could Predict Prostate Cancer Outcome
New method of tracking changes proves better predictor than PSA, study says
Study Supports Pomegranate's Anti-prostate Cancer Potential
The potential of pomegranate extracts and juices to protect against prostate cancer may be due to direct interaction with genes, according to a new study
Study Supports Pomegranate’s Anti-prostate Cancer Potential
The potential of pomegranate extracts and juices to protect against prostate cancer may be due to direct interaction with genes, according to a new study
A study finding that low-income men are more likely to receive diagnoses of advanced prostate cancer was highlighted Jan. 21 on CancerConsultants.com. Dr. William Aronson, clinical professor of urology and a researcher at UCLA’s Jonsson Comprehensive Cancer Center,
was senior author. “Disadvantaged Men Have Less PSA Screening and More Advanced Prostate Cancer at Diagnosis”.
A study finding that low-income men are more likely to receive diagnoses of advanced prostate cancer than affluent men was highlighted Dec. 16 by United Press International, UCLA Newsroom, and NBC affiliates in eight markets. Dr. William Aronson, a clinical professor of urology and a researcher at UCLA’s Jonsson Comprehensive Cancer Center, was senior author of the study.
Men’s News Daily reported Oct. 12 on UCLA research that adds important new information about pomegranate juice’s possible role in the prevention and treatment of prostate cancer. Published in the October issue of Molecular Cancer Therapeutics, the study was led by Dr. Allan Pantuck, a researcher at UCLA’s Jonsson Comprehensive Cancer Center and an associate professor of urology.
Imaging Advance Tracks Prostate Cancer in Lymph Nodes
Engineered "payload" based on common cold virus could aid doctors in treatment decisions. Dr. Lily Wu, a researcher for the UCLA Department of Urology and SPORE investigator, is the study senior author and was featured in this article by the Prostate Cancer Foundation.
Reuters, BBC News, ANI News, AuntMinnie.com, HealthDay News, Genetic Engineering News and the Canadian Broadcasting Company on July 11, the Chinese Daily News and Sing Tao News on July 12, and China’s Xinhua news service on July 14, reported on a study led by Dr. Lily Wu that used an engineered common cold virus to track prostate cancer cells as they spread to the lymph nodes using positron emission tomography. Wu, a researcher at UCLA's Jonsson Comprehensive Cancer Center and an associate professor of pharmacology and urology, was quoted in the coverage. The HealthDay, ANI and BBC stories also appeared in Forbes, HealthCentral.com, Science Daily, PhysOrg.com, the Tehran Times, Thaindian (Thailand), News-Medical.net (Australia), Science News (Canada) and Medical News Today (UK), among others.
Using an engineered common cold virus, UCLA researchers delivered a genetic payload to prostate cancer cells that allowed them, using positron emission tomography (PET), to locate the diseased cells as they spread to the lymph nodes, the first place prostate cancer goes before invading other organs. Dr. Lily Wu, a researcher at the Department of Urology and the Jonsson Comprehensive Cancer Center, was one of the investigators for this study that was featured by the UCLA Newsroom.
HealthDay Spotlights Prostate Cancer Research
HealthDay News reported May 1 on a study by Dr. Pinchas Cohen, a researcher at UCLA’s Jonsson Cancer Center and director of research and training in pediatric endocrinology at Mattel Children's Hospital UCLA. His research highlighted the difficulties involved in blocking the activity of insulin-like growth factor in order to treat prostate cancer. The report also appeared on the web sites for Forbes, the Washington Post, U.S. News & World Report, among others.
A May 15th article featured in the Prostate Cancer Foundation’s newsletter reports that eating less polyunsaturated fat can help prevent prostate cancer in mice. The senior author of the article is Dr. William Aronson, professor of urology and a researcher at the Jonsson Cancer Center at UCLA.
The May 6 issue of Renal & Urology News highlights a study on the spread of prostate cancer conducted by Dr. Robert Reiter, a professor of urology and a researcher at UCLA’s Jonsson Cancer Center. The research appeared in Cancer Research.
A study finding that hormone-refractory prostate cancers are more likely to spread than hormone-dependent cancers was cited in the March 21 issues of the trade publications Drug Week, Biotech Business Week, Oncology Business Week, Preventive Medicine Week, Law & Health Weekly, MD Week, Heath & Medicine Week and Biotech Law Weekly. The study was led by Dr. Robert Reiter, a professor of urology and a researcher at UCLA’s Jonsson Cancer Center.
A study which found that hormone refractory prostate cancers are more likely to spread than hormone dependent cancers was featured Feb. 22 by HealthOrbit.com. The study was led by Dr. Robert Reiter, a professor of urology and a researcher at UCLA’s Jonsson Cancer Center.
Health Day News and Ivanhoe reported Aug. 1, and Reuters Health and United Press International reported Aug. 2 on new animal research showing that altering the typical Western diet to include more omega-3 fatty acids and less omega-6 fatty acids may reduce prostate tumor growth rates and PSA levels. The study was published Aug. 1 in Clinical Cancer Research. Dr. William Aronson, professor of urology and a researcher with the Jonsson Cancer Center, was quoted. The Health Day report also appeared in Forbes.com, CBC News.com (Canada), PhysOrg.com, Health Central.com and Food Consumer.com. The Reuters Health story was picked up by Health Sentinel.com, Gulf News.com, Trade Arabia.com and Cancer Page.com. Other Web coverage included eMaxHealth, Health24, Food Navigator, Best Syndication, News Target (Taiwan) and MedIndia.
"Blood from men who had undergone the low-fat group significantly reduced in vitro growth of LNCaP cells compared to Western diet serum." May 18, 2005 - A high-fat diet and sedentary lifestyle may predispose men to develop prostate cancer through changes in serum hormones and growth factors. In a previous study, researchers from University of California, Los Angeles and Baltimore, MA. showed that blood drawn from men who were limited to a low-fat diet and were exercising reduced serum-stimulated growth of prostate cancer cells in a dish. At the American Urological Association annual meeting this past May, the same research team presented results of another study they designed to see whether a low-fat vs Western diet affects the blood supply's impact on prostate cancer growth. This study also was covered in PSA Rising.
